ID   TOV-2978G
AC   CVCL_9U73
SY   TOV2978G
DR   cancercelllines; CVCL_9U73
DR   Wikidata; Q54972811
RX   PubMed=26622941;
CC   Doubling time: 1.87 +- 0.11 days (PubMed=26622941).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.920-2A>G (IVS8-2A>G); ClinVar=VCV000043595; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=26622941).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson, Anne-Marie.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 12,13
ST   D21S11: 30,33.2
ST   D5S818: 12
ST   D7S820: 10,12
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A1SM ! OV-2978
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 23-02-16; Last updated: 19-12-24; Version: 14
//
RX   PubMed=26622941; DOI=10.18632/genesandcancer.76; PMCID=PMC4633166;
RA   Fleury H., Communal L., Carmona E., Portelance L., Arcand S.L.,
RA   Rahimi K., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Novel high-grade serous epithelial ovarian cancer cell lines that
RT   reflect the molecular diversity of both the sporadic and hereditary
RT   disease.";
RL   Genes Cancer 6:378-398(2015).
//